HBx Promotes the Malignant Advancement of Hepatitis B Virus-Associated Hepatocellular Carcinoma by Increasing ENO1...

Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer, commonly related to chronic hepatitis B virus (HBV) infection. As an essential enzyme in glycolysis, Enolase-1 (ENO1) is implicated in the progression of multiple types of cancer. The aim of this study was to explore the ENO1's function in HBV-associated HCC. The expression of ENO1 in HBV-HCC was determined with RT-qPCR, immunohistochemistry, and Western blot. ENO1 and HBx overexpression or knockdown was performed through transfection. EdU staining, TUNEL staining, wound healing assay, and Transwell assay were utilized to evaluate the malignant biological behavior of HBV-HCC cells. HBV replication in HBV-HCC cells was assessed by measuring HBV DNA, HBsAg, and HBV cccDNA levels. The interaction of HBx with ENO1 was analyzed by co-IP and Western blot analysis. This study showed the elevated ENO1 expression in HBV-HCC. ENO1 overexpression in HBV-HCC cells markedly enhanced proliferation, migration, invasion, and HBV replication, while significantly inhibiting apoptosis. Conversely, ENO1 silencing produced the opposite effects. HBx was found to upregulate ENO1 expression. By rescue assays, HBx silencing suppressed the malignant behavior of HBV-HCC cells, but was reversed by ENO1 overexpression. Additionally, the enhancement of HBx overexpression on the malignant behavior of HBV-HCC cells was counteracted by ENO1 silencing. HBx facilitates the malignant advancement of HBV-associated HCC by elevating ENO1 expression.